LPL Financial
SGMT icon

LPL Financial’s Sagimet Biosciences SGMT Stock Holding History

LPL Financial’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Buy
22,650
+2,076
+10% +$11.6K ﹤0.01% 5643
2025
Q4 		$122K Buy
20,574
+4,899
+31% +$35.2K ﹤0.01% 5562
2025
Q3 		$108K Buy
+15,675
New +$127K ﹤0.01% 5501
2024
Q2 		– Sell
-41,000
Closed -$222K – 5119
2024
Q1 		$222K Buy
+41,000
New +$294K ﹤0.01% 4432

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LPL Financial's SGMT Position: Q1 2026 in Review

LPL Financial increased its Sagimet Biosciences (SGMT) stake by 10% in Q1 2026, buying an estimated $11.6K and bringing the position to 22,650 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #5643.

LPL Financial first reported a position in SGMT in Q1 2024 and has held it in 4 quarters since. The position peaked at $222K in Q1 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • LPL Financial held 22,650 shares of Sagimet Biosciences worth $118K as of Q1 2026.
  • LPL Financial bought 2,076 Sagimet Biosciences shares in Q1 2026, an estimated $11.6K.
  • Sagimet Biosciences made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5643 holding.
  • LPL Financial first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 4 quarters since.
  • LPL Financial's Sagimet Biosciences position peaked at $222K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.